- Home
- ANIX vs OM Comparison
ANIX vs OM Comparison
Compare ANIX & OM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | OM |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 92.9M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANIX | OM |
|---|---|---|
| Price | $2.72 | $4.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.67 | ★ $13.33 |
| AVG Volume (30 Days) | 94.4K | ★ 182.9K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $119,476,000.00 |
| Revenue This Year | N/A | $9.29 |
| Revenue Next Year | N/A | $10.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5.09 |
| 52 Week Low | $2.44 | $3.00 |
| 52 Week High | $5.46 | $21.98 |
Technical Indicators
Market Signals| Indicator | ANIX | OM |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 60.82 |
| Support Level | $2.65 | $4.06 |
| Resistance Level | $3.12 | $4.88 |
| Average True Range (ATR) | 0.12 | 0.36 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 28.21 | 67.33 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.